Clinical Data BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial Pharmaceutical TechnologyAn indirect comparison highlights the potential of BridgeBio's Attruby to best Pfizer's tafamidis in frontline ATTR-CM.CardiovascularRead full story pharminent May 12, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology An indirect comparison highlights the potential of BridgeBio’s Attruby to best Pfizer’s tafamidis in frontline ATTR-CM. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar)Next: Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
